Glenmark Pharmaceuticals Limited
GLENMARK
Rangering i aksjer
#2747
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Aksjekurs
$24.28
Markedsverdi
$6.85B
Endring (1 dag)
-1.65%
Endring (1 år)
14.78%
Land
IN
Handel Glenmark Pharmaceuticals Limited (GLENMARK)
Kategori
Healthcare
Driftsmargin for Glenmark Pharmaceuticals Limited (GLENMARK)
Driftsmargin per October 2026 TTM: 20.24%
Ifølge Glenmark Pharmaceuticals Limited sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 20.24%. Ved slutten av 2024 hadde selskapet en driftsmargin på 26.84%.
Historikk for driftsmargin for Glenmark Pharmaceuticals Limited fra 2004 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 20.24% | -35.36% |
| 2025 | 31.31% | 16.65% |
| 2024 | 26.84% | 182.23% |
| 2023 | 9.51% | -37.84% |
| 2022 | 15.30% | -0.71% |
| 2021 | 15.41% | 28.10% |
| 2020 | 12.03% | -26.56% |
| 2019 | 16.38% | 9.05% |
| 2018 | 15.02% | -10.01% |
| 2017 | 16.69% | 6.51% |
| 2016 | 15.67% | 30.47% |
| 2015 | 12.01% | -19.07% |
| 2014 | 14.84% | -17.09% |
| 2013 | 17.90% | 15.04% |
| 2012 | 15.56% | -28.10% |
| 2011 | 21.64% | -1.23% |
| 2010 | 21.91% | -11.90% |
| 2009 | 24.87% | -29.77% |
| 2008 | 35.41% | 22.65% |
| 2007 | 28.87% | 95.20% |
| 2006 | 14.79% | -28.89% |
| 2005 | 20.80% | 53.96% |
| 2004 | 13.51% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.87% |
IN
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.